ArticleFrontiers in pharmacology2025
Case Report: Near-fatal adverse effects of dopamine agonist for the treatment of restless legs syndrome.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The dopaminergic system plays a central role in motor control, goal-directed behavior, and the pathophysiology of multiple diseases including restless legs syndrome. Dopamine agonists such as pramipexole are commonly prescribed for the treatment of restless legs syndrome; however, growing recognition of potential serious adverse effects has led to updated clinical guidelines which now recommend against the routine use of dopamine agonists as initial therapy. Case Presentation: We present the case of a 64-year-old woman with severe restless legs syndrome and medically unexplained chronic pain who was psychiatrically hospitalized for active suicidal ideation. During her admission, it was discovered that a supratherapeutic dose of pramipexole was the source of iatrogenic harm. Her condition improved following medication taper, appropriate management of restless legs syndrome, and acute psychiatric interventions. Conclusion: Clinicians should be aware of the potential adverse effects associated with dopamine agonists and adhere to updated recommendations for the management of restless legs syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.